Research II on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: A Study on Regulatory Requirements of Pharmacovigilance for Clinical Trial Protocols, Investigator's Brochure and Informed Consent Forms

Zhi Huijing, Zhan Xiaojing, Li Hao, Zuo Xiaochun, Shao Ying, Lü Xinhuan, Zhou Lingyun

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 624-629.

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 624-629. DOI: 10.16153/j.1002-7777.2022.06.004

Research II on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: A Study on Regulatory Requirements of Pharmacovigilance for Clinical Trial Protocols, Investigator's Brochure and Informed Consent Forms

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 36(6): 624-629 https://doi.org/10.16153/j.1002-7777.2022.06.004

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉